Literature DB >> 16785226

Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function.

Viktoria Kheifets1, Rachel Bright, Koichi Inagaki, Deborah Schechtman, Daria Mochly-Rosen.   

Abstract

Protein kinase C (PKC) plays a critical role in diseases such as cancer, stroke, and cardiac ischemia, and participates in a variety of signal transduction pathways such as apoptosis, cell proliferation, and tumor suppression. Though much is known about PKC downstream signaling events, the mechanisms of regulation of PKC activation and subsequent translocation have not been elucidated. Protein-protein interactions regulate and determine the specificity of many cellular signaling events. Such a specific protein-protein interaction is described here between deltaPKC and annexin V. We demonstrate, at physiologically relevant conditions, that a transient interaction between annexin V and deltaPKC occurs in cells after deltaPKC stimulation, but before deltaPKC translocates to the particulate fraction. Evidence of deltaPKC-annexin V binding is provided also by FRET and by in vitro binding studies. Dissociation of the deltaPKC-annexin V complex requires ATP and microtubule integrity. Furthermore, depletion of endogenous annexin V, but not annexin IV, with siRNA inhibits deltaPKC translocation following PKC stimulation. A rationally designed eight amino acid peptide, corresponding to the interaction site for deltaPKC on annexin V, inhibits deltaPKC translocation and deltaPKC-mediated function as evidenced by its protective effect in a model of myocardial infarction. Our data indicate that translocation of deltaPKC is not simply a diffusion-driven process, but is instead a multi-step event regulated by protein-protein interactions. We show that following cell activation, deltaPKC-annexin V binding is a transient and an essential step in the function of deltaPKC, thus identifying a new role for annexin V in PKC signaling and a new step in PKC activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16785226     DOI: 10.1074/jbc.M602075200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide.

Authors:  Tamar Liron; Leon E Chen; Hanita Khaner; Alice Vallentin; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2007-01-24       Impact factor: 5.000

2.  Intracellular peptides as natural regulators of cell signaling.

Authors:  Fernanda M Cunha; Denise A Berti; Zulma S Ferreira; Clécio F Klitzke; Regina P Markus; Emer S Ferro
Journal:  J Biol Chem       Date:  2008-07-10       Impact factor: 5.157

Review 3.  Structural basis of protein kinase C isoform function.

Authors:  Susan F Steinberg
Journal:  Physiol Rev       Date:  2008-10       Impact factor: 37.312

4.  Antimicrobial agent triclosan suppresses mast cell signaling via phospholipase D inhibition.

Authors:  Juyoung K Shim; Molly A Caron; Lisa M Weatherly; Logan B Gerchman; Suraj Sangroula; Siham Hattab; Alan Y Baez; Talya J Briana; Julie A Gosse
Journal:  J Appl Toxicol       Date:  2019-08-19       Impact factor: 3.446

Review 5.  Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases.

Authors:  Opher S Kornfeld; Sunhee Hwang; Marie-Hélène Disatnik; Che-Hong Chen; Nir Qvit; Daria Mochly-Rosen
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

6.  Involvement of protein kinase Cdelta/extracellular signal-regulated kinase/poly(ADP-ribose) polymerase-1 (PARP-1) signaling pathway in histamine-induced up-regulation of histamine H1 receptor gene expression in HeLa cells.

Authors:  Hiroyuki Mizuguchi; Takuma Terao; Mika Kitai; Mitsuhiro Ikeda; Yoshiyuki Yoshimura; Asish Kumar Das; Yoshiaki Kitamura; Noriaki Takeda; Hiroyuki Fukui
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

7.  CGX1037 is a novel PKC isoform delta selective inhibitor in platelets.

Authors:  Dheeraj Bhavanasi; John C Kostyak; John Swindle; Laurie E Kilpatrick; Satya P Kunapuli
Journal:  Platelets       Date:  2014-01-16       Impact factor: 3.862

8.  Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras.

Authors:  T Zhu; T Tsuji; C Chen
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

9.  Mitochondrial import of PKCepsilon is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury.

Authors:  Grant R Budas; Eric N Churchill; Marie-Hélène Disatnik; Lihan Sun; Daria Mochly-Rosen
Journal:  Cardiovasc Res       Date:  2010-06-16       Impact factor: 10.787

Review 10.  Pharmacological characteristics and clinical applications of K201.

Authors:  Noboru Kaneko; Ryuko Matsuda; Yoshihito Hata; Ken Shimamoto
Journal:  Curr Clin Pharmacol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.